Loading
Immune Cells in Cancer · Journal article
Frontiers in Bioinformatics · August 12, 2026
Raises a question worth testing. It does not answer one.
This integrated single-cell meta-analysis identifies compartment-specific lymphocyte remodeling in breast cancer, proposing BTLA-HVEM and CXCL12-CXCR4 signaling as mechanisms of PD-1/PD-L1 resistance. A computational peptide designed to modulate BTLA-HVEM shows favorable in silico binding, but no preclinical or clinical validation is provided.
Integrated meta-analysis of published single-cell RNA-seq datasets with computational structure-guided peptide design. Single-cell RNA-seq profiles from B and T lymphocytes in normal breast tissue, primary breast tumors, tumor-draining lymph nodes, and peripheral blood mononuclear cells; TCGA-BRCA cases for biomarker validation.. Intervention: Computational design of de novo peptide (De novo-P2) targeting BTLA-HVEM signaling axis.. Compared with: Native HVEM (23-39) peptide as structural template; untreated vs. post-therapy immune compartments..
Tumors enriched for effector CD8 states (CD8 cytotoxic 20.1%; CD8 activated 13.5%), whereas tumor-draining lymph nodes preserved larger naïve and memory reservoirs (CD4 naïve 40.7%; B naïve 11.4%; B memory 12.0%) Tumor-draining lymph nodes contained higher B cell fraction than tumors (39.6% vs. 19.5%) Post-therapy, peripheral blood and lymph nodes showed increased BTLA-HVEM and MIF-CD74 checkpoint signaling with shift from CD44 toward CXCR4
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The proposed BTLA-HVEM and CXCR4-CXCL12 signatures merit investigation as predictive biomarkers for PD-1/PD-L1 resistance, but the de novo peptide remains preclinical and requires functional validation before clinical translation. These findings should prompt prospective studies to validate the biomarker associations and test peptide-based intervention.
A single-cell meta-analysis identifying compartment-specific immune signatures and proposing therapeutic targets through computational design, without experimental validation of the peptide or clinical trial evidence.
As stated by the source record.
Quoted from the source exactly as published.
The proposed BTLA-HVEM and CXCR4-CXCL12 signatures merit investigation as predictive biomarkers for PD-1/PD-L1 resistance, but the de novo peptide remains preclinical and requires functional validation before clinical translation. These findings should prompt prospective studies to validate the biomarker associations and test peptide-based intervention.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Metastatic breast cancer remains difficult to cure, and the way B and T lymphocytes adapt across metastatic niches especially under therapy remains insufficiently defined. Clarifying compartment specific immune remodeling may help explain resistance to PD-1/PD-L1 blockade and identify actionable targets. We performed an integrated meta-analysis of single cell RNA-seq datasets from normal breast tissue, primary tumors, tumor-draining lymph nodes (TLNs), and peripheral blood mononuclear cells (PBMCs), focusing on B and Tcell states. Immune composition differed notably by compartment. Tumors were enriched for effector CD8 states (CD8 cytotoxic 20.1%; CD8 activated 13.5%), whereas TLNs preserved larger naïve and memory reservoirs (CD4 naïve 40.7%; B naïve 11.4%; B memory 12.0%) and contained a higher B cell fraction than tumors (39.6% vs. 19.5%). Post therapy, PBMCs and TLNs showed increased BTLA-HVEM (TNFRSF14) checkpoint signaling and enhanced MIF-CD74 interactions with a shift from CD44 toward CXCR4, consistent with CXCR4 driven migratory and survival programs. In TLNs, TNFRSF14 signaling was unidirectional (B→T), absent in the reverse direction, and not detected in tumors. Clinically, higher tumor CXCR4 combined with lower TNFRSF14 was associated with shorter progression free survival in TCGA-BRCA, most evident in node positive, early stage disease. To target the BTLA-HVEM checkpoint axis, we performed structure guided de novo peptide design using the native HVEM (23-39) peptide as an active structural template, followed by docking and molecular dynamics simulations. The optimized De novo-P2 peptide showed stable and favorable interactions at the BTLA interface, supporting its potential as a competitive modulator of BTLA-HVEM signaling. These data define niche specific lymphocyte remodeling and implicate BTLA-HVEM and CXCL12-CXCR4 as candidate biomarkers and therapeutic targets linked to PD-1/PD-L1 resistance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.